What other FDA‑approved pharmacologic agents can be used for weight loss besides tirzepatide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

FDA-Approved Weight Loss Medications Beyond Tirzepatide

For adults with obesity or overweight with comorbidities, the FDA-approved alternatives to tirzepatide include GLP-1 receptor agonists (semaglutide 2.4 mg weekly and liraglutide 3.0 mg daily), phentermine-topiramate, naltrexone-bupropion, and orlistat, with semaglutide demonstrating the most robust weight loss and cardiovascular benefits after tirzepatide. 1

Highest Efficacy Options: GLP-1 Receptor Agonists

Semaglutide (Subcutaneous, 2.4 mg weekly)

  • Produces approximately 15% mean weight loss at 68 weeks 1
  • Demonstrated superior cardiovascular outcomes in the SELECT trial: among 17,604 participants with cardiovascular disease and BMI ≥27 without diabetes, semaglutide reduced the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% (HR 0.80; 95% CI 0.72-0.90) at 39.8 months 1
  • Improved heart failure symptoms and physical limitations in patients with preserved ejection fraction 1
  • Significantly more effective than liraglutide with lower gastrointestinal adverse event rates 1

Liraglutide (Subcutaneous, 3.0 mg daily)

  • Produces mean weight loss of 8.0% at 56 weeks (5.4% more than placebo) 1
  • Daily dosing may be preferred by some patients despite lower efficacy
  • More widely available and often lower cost than semaglutide 1
  • Both GLP-1 agonists reduce cardiovascular events in adults with overweight/obesity without diabetes (8.7% vs 11.2% placebo at 32-160 weeks follow-up) 1

Moderate Efficacy Options

Phentermine-Topiramate (Oral, daily)

  • FDA approved 2012; produces 10.9% weight loss at 56 weeks with the 15/92 mg dose (5.1% with lower 3.75/23 mg dose) 1
  • Mechanism: phentermine enhances norepinephrine release and blocks reuptake; topiramate alters appetite and decreases energy intake 1
  • Particularly useful for patients with comorbid migraine headaches since topiramate prevents migraines 1
  • Systematic reviews show greater weight loss compared to orlistat and naltrexone-bupropion 1

Naltrexone-Bupropion (Oral, 32/360 mg daily)

  • FDA approved 2014; achieves approximately 6% weight loss at 56 weeks (vs 1% placebo) 1
  • Mechanism: bupropion stimulates hypothalamic proopiomelanocortin neurons while naltrexone blocks opioid-mediated autoinhibition, reducing food cue reactivity and improving eating control dysregulation 1
  • Consider for patients with comorbid depression, smoking cessation needs, or alcohol use reduction goals 1

Orlistat (Oral, pancreatic lipase inhibitor)

  • Oldest FDA-approved option but currently used less frequently due to lower efficacy and significant gastrointestinal side effects 1, 2
  • Less effective than other available options 1

Clinical Decision Algorithm

First-line choice: Semaglutide 2.4 mg weekly for maximal weight loss and proven cardiovascular benefit, especially in patients with or at risk for cardiovascular disease 1

Second-line or cost-limited: Liraglutide 3.0 mg daily if semaglutide unavailable or unaffordable 1

Comorbidity-matched selection:

  • Migraine headaches → phentermine-topiramate 1
  • Depression or smoking cessation → naltrexone-bupropion 1
  • Cardiovascular disease → semaglutide (proven outcomes) 1

Important considerations: All GLP-1 agonists carry gastrointestinal side effects (nausea, vomiting, diarrhea) that typically improve with dose titration. Phentermine-topiramate requires contraception due to teratogenicity of topiramate. 1, 2

Comparative Effectiveness

A meta-analysis of 12,371 adults demonstrated tirzepatide 15 mg weekly produced 5.1% more weight loss than semaglutide 2.4 mg weekly and 13.0% more than liraglutide 3.0 mg daily 1. Among non-tirzepatide options, phentermine-topiramate demonstrates superior weight loss compared to naltrexone-bupropion and orlistat 1.

Common Pitfalls

  • Failing to match medication to patient comorbidities (missing opportunities for dual benefit)
  • Inadequate dose titration leading to poor tolerability
  • Not counseling on gastrointestinal side effects with GLP-1 agonists
  • Prescribing topiramate-containing products without ensuring contraception in reproductive-age women
  • Overlooking cardiovascular benefits of semaglutide when selecting agents for high-risk patients

References

Related Questions

What alternative pharmacotherapy options are available for obesity management in a patient who cannot continue tirzepatide?
What are the recommended pharmacologic agents for obesity management, including indications, dosing, contraindications, and monitoring parameters?
What are the evidence‑based medical weight‑management options for a patient interested in treatment?
Which weight‑loss medications (and are any antibiotics appropriate) can be prescribed for an adult patient with excess weight?
Is it safe and appropriate to combine Zepbound (tirzepatide) with phentermine for weight loss in an adult patient without contraindications?
Can zolpidem induce fever, and should it be discontinued if fever develops while taking it?
In a patient with type 2 diabetes on losartan, does tirzepatide (Mounjaro) cause a decline in kidney function?
Can melatonin cause fever in a patient who recently started the supplement?
How should I manage a patient with fever, eosinophilia, acute ischemic stroke, and atrial fibrillation?
How should stimulants be used to manage agitation in a child with autism, including appropriate dosing, titration, monitoring for side effects, and alternative treatment options?
What are the target ferritin levels for adults without chronic kidney disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.